Meet the CEO of a Confident Orphan Oncology Biotech from France & Denmark

22/02/2016 - 4 minutes

Last week, I was in Paris to meet with one of our Investors, during which time I also had a chance to visit the French Cancer Biotech, Onxeo.

onxeo_oncology_interview_beleodaq_ceo_livatag_valdiveI met with the CEO of Onxeo, Judith Greciet, who was confident about the future of the company.

She moved into the role in 2011 after having spent several years in mid-size Pharma and being a French director of Eisai (Japan).

Onxeo originates from the merger of Paris-based BioAlliance Pharma and Topotarget (Denmark). The company has three small-molecule products: Livatag (phase III trial for Liver cancer), Beleodaq (approved in PTCL 2nd line, successful phase I results in first line just announced) and Validive (Phase II).

You seem to have a robust pipeline. What are the future steps of development?

Following our announce in December, we are working on the Phase III of Beleodaq (Belinostat) in combination with the reference treatment as first line treatment (first treatment,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member